In hepatocellular carcinoma, the restoration of OXPHOS by Cox6a2 or Cox15 overexpression and/or inhibition of FAO by etomoxir sensitized CSCs to sorafenib treatment, suggesting that reprogramming CSC metabolism by either OXPHOS restoration or FAO inhibition can be an effective therapy in these tumours (Chen et al., 2016) (Fig. 2). The gene discussed is COX6A2; the disease is hepatocellular carcinoma.